- Home
- RCS vs SLP Comparison
RCS vs SLP Comparison
Compare RCS & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- SLP
- Stock Information
- Founded
- RCS 1994
- SLP 1996
- Country
- RCS United States
- SLP United States
- Employees
- RCS N/A
- SLP N/A
- Industry
- RCS Investment Managers
- SLP EDP Services
- Sector
- RCS Finance
- SLP Technology
- Exchange
- RCS Nasdaq
- SLP Nasdaq
- Market Cap
- RCS 358.4M
- SLP 322.4M
- IPO Year
- RCS N/A
- SLP 1997
- Fundamental
- Price
- RCS $7.46
- SLP $15.26
- Analyst Decision
- RCS
- SLP Buy
- Analyst Count
- RCS 0
- SLP 8
- Target Price
- RCS N/A
- SLP $26.80
- AVG Volume (30 Days)
- RCS 141.1K
- SLP 657.0K
- Earning Date
- RCS 01-01-0001
- SLP 10-23-2025
- Dividend Yield
- RCS 10.12%
- SLP N/A
- EPS Growth
- RCS N/A
- SLP N/A
- EPS
- RCS N/A
- SLP N/A
- Revenue
- RCS N/A
- SLP $80,383,000.00
- Revenue This Year
- RCS N/A
- SLP $12.76
- Revenue Next Year
- RCS N/A
- SLP $2.82
- P/E Ratio
- RCS N/A
- SLP N/A
- Revenue Growth
- RCS N/A
- SLP 20.01
- 52 Week Low
- RCS $4.51
- SLP $12.39
- 52 Week High
- RCS $6.31
- SLP $37.67
- Technical
- Relative Strength Index (RSI)
- RCS 47.08
- SLP 49.56
- Support Level
- RCS $7.53
- SLP $14.73
- Resistance Level
- RCS $7.78
- SLP $16.80
- Average True Range (ATR)
- RCS 0.18
- SLP 0.67
- MACD
- RCS -0.04
- SLP -0.05
- Stochastic Oscillator
- RCS 21.50
- SLP 33.98
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.